Adrb2 gene polymorphisms and salbutamol responsiveness in Serbian children with asthma

Inhaled beta 2 adrenergic receptor (beta 2-AR) agonists are the mainstay of asthma therapy. The beta 2-AR protein is encoded by the ADRB2 gene and variants within this gene can have significant consequences for modulating the response to asthma therapy. This cross-sectional study performed at the University Children's Hospital in Belgrade, included 54 children with asthma. The subjects were genotyped for ADRB2 +46A gt G (Arg16Gly, rs1042713) and +79C gt G (G1n27G1u, rs1042714) polymorphisms and the association with asthma severity and response to inhaled salbutamol was examined. In Serbian asthmatic children, allele +46A was detected with a frequency of 41.7% and allele +79G was detected with a frequency of 23.1%. Allele +460 was found to be associated with a better response to inhaled salbutamol (p lt 0.05) and with mild form of asthma (p lt 0.05). Polymorphism ADRB2 +46A gt G may be a determinant of asthma severity and response to salbutamol in children with asthma. We did not find any association of +79C gt G polymorphisms with the asthma severity and bronchodilator response to inhaled salbutamol. The results of this study can be potentially useful for personalization of asthma treatment